4D Molecular Therapeutics Inc
NASDAQ:FDMT
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Price:
8.48
USD
1.8%
Market Cap:
$432.6m
Balance Sheet
Balance Sheet Decomposition
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Balance Sheet Decomposition is not available for
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Balance Sheet
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
|
| Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
95
|
161
|
39
|
276
|
|
| Total Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
4
|
9
|
7
|
8
|
10
|
|
| Total Current Assets |
25
|
94
|
53
|
283
|
256
|
221
|
297
|
435
|
|
| PP&E Net |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
|
| PP&E Gross |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
|
| Accumulated Depreciation |
1
|
2
|
3
|
4
|
5
|
8
|
12
|
17
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
68
|
5
|
11
|
81
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
|
| Total Assets |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
1
|
2
|
2
|
5
|
3
|
4
|
4
|
|
| Accrued Liabilities |
1
|
2
|
3
|
5
|
7
|
10
|
14
|
22
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
5
|
6
|
8
|
10
|
4
|
2
|
2
|
3
|
|
| Total Current Liabilities |
6
|
8
|
13
|
17
|
16
|
16
|
19
|
29
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
23
|
14
|
15
|
15
|
18
|
15
|
13
|
21
|
|
| Total Liabilities |
28
N/A
|
22
-24%
|
28
+31%
|
32
+13%
|
34
+8%
|
31
-11%
|
32
+5%
|
50
+55%
|
|
| Equity | |||||||||
| Common Stock |
19
|
103
|
103
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
21
|
30
|
79
|
136
|
207
|
315
|
415
|
576
|
|
| Additional Paid In Capital |
1
|
2
|
6
|
392
|
527
|
547
|
723
|
1 087
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
1
N/A
|
75
N/A
|
30
-60%
|
256
+755%
|
319
+24%
|
231
-28%
|
308
+33%
|
511
+66%
|
|
| Total Liabilities & Equity |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
27
|
32
|
33
|
43
|
46
|
|
Switch to:
Switch to:
See Also
Discover More
